Free Trial
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel
NASDAQ:VSTM

Verastem Q3 2026 Earnings Date & Estimates

Verastem logo
$8.30 +0.19 (+2.31%)
As of 09:46 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Verastem is scheduled to report Q3 2026 earnings on Tuesday, November 3, 2026, after market closes. The conference call is scheduled for 8:00 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
8:00 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Verastem in Q3 2026

Verastem is expected to post earnings of -$0.44 per share on revenue of $29.32 million. In the same quarter a year earlier Verastem reported -$1.35 per share on revenue of $11.24 million. Verastem last reported on August 6, 2026, posting -$0.35 per share and beating the -$0.43 consensus estimate. Verastem has beaten the consensus EPS estimate in 4 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.44
Expected Revenue
$29.32 million
Prior-Year EPS
-$1.35
Prior-Year Revenue
$11.24 million
Expected Revenue Growth
+160.8%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.35 (Beat by +$0.08)
Last Quarter Revenue
$40.08 million
EPS Beat Rate
4 of last 8 quarters

Prepare for the Q3 2026 Call

Verastem Q3 2026 Earnings FAQ

Verastem (NASDAQ:VSTM) is scheduled to report Q3 2026 earnings on Tuesday, November 3, 2026, after market closes.

Verastem's Q3 2026 earnings conference call is scheduled for Tuesday, November 3, 2026 at 8:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Verastem to post earnings of -$0.44 per share for Q3 2026.

The consensus revenue estimate for Verastem is $29.32 million for Q3 2026.

Verastem Earnings Headlines

Verastem: A Two-For-One Clinical Readout In October And A Commercial Launch
October 6 at 4:51 AM  |  seekingalpha.comhttps://seekingalpha.com/article/4952135-verastem-a-two-for-one-clinical-readout-in-october-and-a-commercial-launch?utm_source=marketbeat.com&utm_medium=referral&feed_item_type=article?source=MarketBeat
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 5, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20261002207190/en/verastem-oncology-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4/
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.tc pixel
October 9 at 1:00 AM  |  Altimetry (Ad)
Verastem (NASDAQ:VSTM) Stock Keeps "Buy" Rating at BTIG Research
October 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31086575
Verastem (NASDAQ:VSTM) Earns Buy Rating from HC Wainwright
October 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31086567
Durable Efficacy Data in LGSOC Reinforce Verastem Franchise and Label Expansion Potential; Buy Rating Reiterated with Unchanged $18 Price Target
October 5, 2026  |  tipranks.comhttps://www.tipranks.com/news/ratings/durable-efficacy-data-in-lgsoc-reinforce-verastem-franchise-and-label-expansion-potential-buy-rating-reiterated-with-unchanged-18-price-target-ratings-news?utm_source=marketbeat.com&utm_medium=referral
See More Verastem Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Verastem? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Verastem and other key companies, straight to your email.

About Verastem

Verastem (NASDAQ:VSTM) Oncology (NASDAQ:VSTM) is a biopharmaceutical company focused on developing and commercializing targeted therapies for cancers driven by abnormalities in the RAS/MAPK signaling pathway. The company’s research is aimed at addressing cancers with limited treatment options, including ovarian cancer and other solid tumors.

Verastem’s lead product, avutometinib, is a treatment targeting the RAF/MEK signaling pathway and is marketed in the United States under the brand name Avmapki for certain patients with recurrent low-grade serous ovarian cancer. The company has also developed defactinib, an investigational focal adhesion kinase inhibitor being evaluated in combination with avutometinib and other therapies for selected cancers.

Founded in 2010, Verastem is headquartered in Needham, Massachusetts. Its operations and clinical development activities have included collaborations and trials involving medical institutions and patients in the United States and other international markets. Dan Paterson serves as the company’s president and chief executive officer.

View Verastem Profile
Earnings Tools